Dynavax Technologies CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Dynavax Technologies Corporation reported a 53% increase in net income for Q3 2025 driven by robust HEPLISAV-B sales, despite a nine-month net loss due to a significant debt extinguishment charge and bad debt expense.
Dynavax Technologies Corporation reported a significant increase in Q2 2025 product revenue, driven by HEPLISAV-B sales, despite a net loss for the six-month period due to debt extinguishment and bad debt expense.
Dynavax Technologies reports a net loss for Q1 2025, influenced by a loss on debt extinguishment and an allowance for doubtful accounts related to Clover.
Dynavax Technologies reported a net income of $17.6 million for the third quarter of 2024, driven by a 27% increase in HEPLISAV-B product revenue compared to the same period last year.
Dynavax Technologies saw a significant increase in revenue in the second quarter of 2024, primarily driven by sales of its HEPLISAV-B vaccine.
Dynavax Technologies reported a net loss of $8.7 million for Q1 2024, with HEPLISAV-B product revenue increasing to $47.8 million.